Niagen Bioscience Inc (NAGE)

$3.29 -0.18 (-5.19%)
Market Cap 276.37M
Revenue (ttm) 129.42M
Net Income (ttm) 17.38M
EPS (ttm) N/A
PE Ratio 17.84
Forward PE 15.65
Profit Margin 13.43%
Debt to Equity Ratio 0.00
Volume 861,900
Avg Vol 894,592
Day's Range N/A - N/A
Shares Out 79.64M
Stochastic %K 15%
Beta 2.09
Analysts Strong Sell
Price Target $10.80

Company Profile

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, in...

Industry: Biotechnology
Sector: Healthcare
Phone: 310 388 6706
Address:
10900 Wilshire Blvd, Suite 600, Los Angeles, United States
wycliff
wycliff Jul. 14 at 8:48 PM
$NAGE https://clinicaltrials.gov/study/NCT07703137
1 · Reply
wycliff
wycliff Jul. 14 at 4:14 PM
$NAGE https://finance.yahoo.com/community/post/49689d6f-4de4-4010-87e3-f5d54a71e325
0 · Reply
wycliff
wycliff Jul. 14 at 4:02 PM
$NAGE https://www.linkedin.com/posts/receiving-rpd-designation-from-the-us-share-7482803623450742784-OTzE/?utm_source=share&utm_medium=member_ios&rcm=ACoAAAUGerIBOiyuZoO-6U9HRKRzZ48AD8YnjZA
0 · Reply
wycliff
wycliff Jul. 14 at 3:51 PM
$NAGE in response to impalas283 message maybe your answer is because they might be using NRH which is supposedly superior or an improvement over just using NR and they have the patents on it as well
1 · Reply
Impalas283
Impalas283 Jul. 14 at 12:56 PM
$NAGE The latest news does not make sense to me. The studies for these orphan diseases used Nicotine Riboside Chloride, (Tru Niagen) to obtain the results. Why wouldn't people with these diseases just use Tru Niagen Instead of an expensive prescription? Just another reason why people have lost faith in this company. Even long term holders are bailing out.
2 · Reply
wycliff
wycliff Jul. 14 at 12:20 AM
$NAGE https://finance.yahoo.com/community/post/1b995225-98af-4839-babe-44d28d74ff32
0 · Reply
MattManzanita
MattManzanita Jul. 13 at 11:56 PM
$NAGE Smart short sellers are getting out, but getting out too easily IMO: May be an image of text that says 'NAGE / Short Interest Niagen Bioscience, Inc. Common Stock (NAGE) Short Interest Settlement Short Interest 06/15/2026 4,394,606 Avg. Daily Share Volume 05/29/2026 4,498,798 789,556 05/15/2026- 4,715,950 652,114 04/30/2026 - 4,990,181 993 04/15/2026 - 5,401,652 126 03/31/2026- 5,453,364 5,453 03/13/2026- 5,496,661 598, 02/27/2026 -5,578,868 1,235, 02/13/2026 - 6,457,826 2,530, \ · Shorts have been steadily backing out since Valentines Day: They are squirming out of the net too easily.
0 · Reply
wycliff
wycliff Jul. 13 at 9:11 PM
$NAGE https://www.linkedin.com/posts/niagen-bioscience-announced-that-the-us-share-7482529797496209408-6IN3/?utm_source=share&utm_medium=member_ios&rcm=ACoAAAUGerIBOiyuZoO-6U9HRKRzZ48AD8YnjZA
0 · Reply
wycliff
wycliff Jul. 13 at 7:21 PM
$NAGE
0 · Reply
wycliff
wycliff Jul. 13 at 7:20 PM
$NAGE https://finance.yahoo.com/community/post/21f8de8b-4762-430e-ab69-7ad829a842b8
0 · Reply
Latest News on NAGE
Niagen Bioscience receives exclusive U.S. RPD, EMA OMPD for NB4168

2026-07-13T12:35:07.000Z - 1 day ago

Niagen Bioscience receives exclusive U.S. RPD, EMA OMPD for NB4168

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)

Jul 13, 2026, 8:32 AM EDT - 1 day ago

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)

Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026

Jul 9, 2026, 8:32 AM EDT - 5 days ago

Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026

Niagen Bioscience launches pharmaceutical program for aging and genetic diseases

2026-07-08T12:40:25.000Z - 6 days ago

Niagen Bioscience launches pharmaceutical program for aging and genetic diseases

Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases

Jul 8, 2026, 8:32 AM EDT - 6 days ago

Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases

Niagen Bioscience initiated with a Buy at Freedom Broker

2026-07-06T19:10:21.000Z - 8 days ago

Niagen Bioscience initiated with a Buy at Freedom Broker

Niagen Bioscience Registration statement: Registration filing

Jun 29, 2026, 8:00 AM EDT - 15 days ago

Niagen Bioscience Registration statement: Registration filing

Niagen Bioscience files $125M mixed securities shelf

2026-06-29T10:25:42.000Z - 15 days ago

Niagen Bioscience files $125M mixed securities shelf

Niagen Bioscience Transcript: 16th Annual East Coast IDEAS Conference

Jun 11, 2026, 2:40 PM EDT - 4 weeks ago

Niagen Bioscience Transcript: 16th Annual East Coast IDEAS Conference

Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference

Jun 3, 2026, 8:34 AM EDT - 5 weeks ago

Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference

Niagen Bioscience renames CERP to Niagen Research Program

2026-06-02T15:25:33.000Z - 6 weeks ago

Niagen Bioscience renames CERP to Niagen Research Program

Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science

Jun 2, 2026, 8:32 AM EDT - 6 weeks ago

Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science

Niagen Bioscience price target lowered to $11 from $12 at H.C. Wainwright

2026-05-11T10:46:50.000Z - 2 months ago

Niagen Bioscience price target lowered to $11 from $12 at H.C. Wainwright

Niagen Bioscience Announces Participation in Upcoming Investor Conferences

May 8, 2026, 8:32 AM EDT - 2 months ago

Niagen Bioscience Announces Participation in Upcoming Investor Conferences

Niagen Bioscience price target lowered to $12 from $13 at Roth Capital

2026-05-07T20:07:38.000Z - 2 months ago

Niagen Bioscience price target lowered to $12 from $13 at Roth Capital

Niagen Bioscience reports Q1 EPS 7c, consensus 6c

2026-05-07T01:51:30.000Z - 2 months ago

Niagen Bioscience reports Q1 EPS 7c, consensus 6c

Niagen Bioscience sees 2026 sales growth 10%-15%

2026-05-07T01:50:48.000Z - 2 months ago

Niagen Bioscience sees 2026 sales growth 10%-15%

Niagen Bioscience Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Niagen Bioscience Earnings Call Transcript: Q1 2026

Niagen Bioscience Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Niagen Bioscience Quarterly report: Q1 2026

Niagen Bioscience Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Niagen Bioscience Earnings release: Q1 2026

Niagen Bioscience Slides: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Niagen Bioscience Slides: Q1 2026

Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

May 6, 2026, 4:02 PM EDT - 2 months ago

Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

Niagen Bioscience Slides: Corporate presentation

May 6, 2026, 7:00 AM EDT - 2 months ago

Niagen Bioscience Slides: Corporate presentation

Niagen Bioscience price target lowered to $10 from $13 at Canaccord

2026-05-05T11:04:12.000Z - 2 months ago

Niagen Bioscience price target lowered to $10 from $13 at Canaccord

Niagen Bioscience launches Niagen Plus telehealth plarform

2026-05-04T13:07:08.000Z - 2 months ago

Niagen Bioscience launches Niagen Plus telehealth plarform

Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering

May 4, 2026, 8:32 AM EDT - 2 months ago

Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering

Niagen Bioscience Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Niagen Bioscience Proxy statement: Proxy filing

Niagen Bioscience Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Niagen Bioscience Proxy statement: Proxy filing

Niagen Bioscience announces new partnership with Olympia Pharmaceuticals

2026-04-28T12:57:11.000Z - 2 months ago

Niagen Bioscience announces new partnership with Olympia Pharmaceuticals

Niagen Bioscience announces new partnership with Olympia Pharmaceuticals

2026-04-28T12:51:55.000Z - 2 months ago

Niagen Bioscience announces new partnership with Olympia Pharmaceuticals

Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™

Apr 28, 2026, 8:32 AM EDT - 2 months ago

Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™

Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

Apr 22, 2026, 8:32 AM EDT - 2 months ago

Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

Niagen Bioscience collaborates with USP to establish USP monograph

2026-04-09T14:14:54.000Z - 3 months ago

Niagen Bioscience collaborates with USP to establish USP monograph

Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®

Apr 9, 2026, 8:32 AM EDT - 3 months ago

Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®

Niagen announces first cruise ship clinic partnership with OneSpaWorld

2026-03-31T13:06:28.000Z - 3 months ago

Niagen announces first cruise ship clinic partnership with OneSpaWorld

OSW

Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas

Mar 31, 2026, 8:34 AM EDT - 3 months ago

Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas

OSW

Niagen Bioscience increases share repurchase program to $20M

2026-03-19T12:50:32.000Z - 4 months ago

Niagen Bioscience increases share repurchase program to $20M

Niagen Bioscience Increases Share Repurchase Program to $20 Million

Mar 19, 2026, 8:32 AM EDT - 4 months ago

Niagen Bioscience Increases Share Repurchase Program to $20 Million

Niagen Bioscience to Present at the 38th Annual ROTH Conference

Mar 18, 2026, 8:32 AM EDT - 4 months ago

Niagen Bioscience to Present at the 38th Annual ROTH Conference

Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies

Mar 17, 2026, 8:32 AM EDT - 4 months ago

Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies

Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®

Mar 10, 2026, 8:32 AM EDT - 4 months ago

Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®

Niagen Bioscience price target lowered to $13 from $14 at Canaccord

2026-03-05T11:40:40.000Z - 4 months ago

Niagen Bioscience price target lowered to $13 from $14 at Canaccord

Niagen Bioscience sees FY26 revenue up 10%-15%, implying $142.3M-$148.8M

2026-03-04T21:45:41.000Z - 4 months ago

Niagen Bioscience sees FY26 revenue up 10%-15%, implying $142.3M-$148.8M

Niagen Bioscience up 39% at $6.88 after Q4 results and guidance

2026-03-04T21:45:21.000Z - 4 months ago

Niagen Bioscience up 39% at $6.88 after Q4 results and guidance

Niagen Bioscience Earnings Call Transcript: Q4 2025

Mar 4, 2026, 4:30 PM EST - 4 months ago

Niagen Bioscience Earnings Call Transcript: Q4 2025

Niagen Bioscience Annual report: Q4 2025

Mar 4, 2026, 4:30 PM EST - 4 months ago

Niagen Bioscience Annual report: Q4 2025

Niagen Bioscience Earnings release: Q4 2025

Mar 4, 2026, 4:30 PM EST - 4 months ago

Niagen Bioscience Earnings release: Q4 2025

Niagen Bioscience Slides: Q4 2025

Mar 4, 2026, 4:30 PM EST - 4 months ago

Niagen Bioscience Slides: Q4 2025

Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025

Mar 4, 2026, 4:02 PM EST - 4 months ago

Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025

Niagen Bioscience Slides: Corporate presentation

Mar 4, 2026, 7:00 AM EST - 4 months ago

Niagen Bioscience Slides: Corporate presentation

Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction

Feb 26, 2026, 7:02 AM EST - 4 months ago

Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction

Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®

Feb 25, 2026, 8:32 AM EST - 4 months ago

Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®

Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen

Feb 9, 2026, 8:34 AM EST - 5 months ago

Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen

Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026

Feb 6, 2026, 8:32 AM EST - 5 months ago

Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026

Niagen Bioscience Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

Jan 15, 2026, 11:30 AM EST - 6 months ago

Niagen Bioscience Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*

Jan 15, 2026, 8:34 AM EST - 6 months ago

Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*

Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen's University Belfast

Dec 22, 2025, 8:32 AM EST - 7 months ago

Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen's University Belfast

Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)

Nov 13, 2025, 8:32 AM EST - 8 months ago

Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)

Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID

Nov 12, 2025, 7:52 PM EST - 8 months ago

Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID

Niagen Bioscience Announces $10 Million Share Repurchase Program

Nov 6, 2025, 8:07 AM EST - 8 months ago

Niagen Bioscience Announces $10 Million Share Repurchase Program

Niagen Bioscience Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 9 months ago

Niagen Bioscience Earnings Call Transcript: Q3 2025

Niagen Bioscience Earnings release: Q3 2025

Nov 4, 2025, 4:30 PM EST - 9 months ago

Niagen Bioscience Earnings release: Q3 2025

Niagen Bioscience Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 9 months ago

Niagen Bioscience Quarterly report: Q3 2025

Niagen Bioscience Slides: Q3 2025

Nov 4, 2025, 4:30 PM EST - 9 months ago

Niagen Bioscience Slides: Q3 2025

Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook

Nov 4, 2025, 4:02 PM EST - 9 months ago

Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook

Niagen Bioscience Slides: Investor presentation

Nov 4, 2025, 7:00 AM EST - 9 months ago

Niagen Bioscience Slides: Investor presentation

Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Oct 21, 2025, 8:32 AM EDT - 9 months ago

Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth

Oct 6, 2025, 8:32 AM EDT - 10 months ago

Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide

Oct 1, 2025, 8:32 AM EDT - 10 months ago

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide

AboutNADⓇ Debuts as the Leading Online Resource for Scientific Advancements in NAD+

Sep 16, 2025, 8:32 AM EDT - 10 months ago

AboutNADⓇ Debuts as the Leading Online Resource for Scientific Advancements in NAD+

Niagen Bioscience Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 12, 2025, 12:00 PM EDT - 1 year ago

Niagen Bioscience Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Niagen Bioscience Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Earnings Call Transcript: Q2 2025

Niagen Bioscience Earnings release: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Earnings release: Q2 2025

Niagen Bioscience Quarterly report: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Quarterly report: Q2 2025

Niagen Bioscience Slides: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Slides: Q2 2025

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

Aug 6, 2025, 4:02 PM EDT - 1 year ago

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

Niagen Bioscience to Present at Canaccord Genuity's 45th Annual Growth Conference

Aug 4, 2025, 8:32 AM EDT - 1 year ago

Niagen Bioscience to Present at Canaccord Genuity's 45th Annual Growth Conference

Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Jul 23, 2025, 8:34 AM EDT - 1 year ago

Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York

Jul 14, 2025, 8:32 AM EDT - 1 year ago

Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York

Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson's Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway

Jul 8, 2025, 8:32 AM EDT - 1 year ago

Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson's Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway

Niagen Bioscience to Participate at the Roth 15th Annual London Conference

Jun 20, 2025, 8:32 AM EDT - 1 year ago

Niagen Bioscience to Participate at the Roth 15th Annual London Conference

Niagen Bioscience to Participate in the BIO 2025 International Convention

Jun 11, 2025, 8:31 AM EDT - 1 year ago

Niagen Bioscience to Participate in the BIO 2025 International Convention

Niagen Bioscience Transcript: 25th Annual Consumer Growth and E-Commerce Conference

Jun 9, 2025, 2:15 PM EDT - 1 year ago

Niagen Bioscience Transcript: 25th Annual Consumer Growth and E-Commerce Conference

Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder

Jun 9, 2025, 8:32 AM EDT - 1 year ago

Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder

Niagen Bioscience to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference

Jun 4, 2025, 8:32 AM EDT - 1 year ago

Niagen Bioscience to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference

Niagen Bioscience Slides: Corporate Presentation

May 9, 2025, 7:00 AM EDT - 1 year ago

Niagen Bioscience Slides: Corporate Presentation

Niagen Bioscience Earnings Call Transcript: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Earnings Call Transcript: Q1 2025

Niagen Bioscience Earnings release: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Earnings release: Q1 2025

Niagen Bioscience Quarterly report: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Quarterly report: Q1 2025

Niagen Bioscience Slides: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Slides: Q1 2025

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

May 7, 2025, 4:02 PM EDT - 1 year ago

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide

May 5, 2025, 8:32 AM EDT - 1 year ago

Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide

Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

Apr 29, 2025, 8:32 AM EDT - 1 year ago

Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

Niagen Bioscience Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Niagen Bioscience Proxy statement: Proxy Filing

Niagen Bioscience Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Niagen Bioscience Proxy statement: Proxy Filing

Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

Apr 28, 2025, 8:34 AM EDT - 1 year ago

Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs

Apr 7, 2025, 10:32 PM EDT - 1 year ago

Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs

Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments

Apr 7, 2025, 8:32 AM EDT - 1 year ago

Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms

Mar 20, 2025, 8:34 AM EDT - 1 year ago

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms

ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science

Mar 19, 2025, 8:34 AM EDT - 1 year ago

ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science

Niagen Bioscience Slides: Corporate Presentation

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Niagen Bioscience Slides: Corporate Presentation

ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025

Mar 13, 2025, 8:34 AM EDT - 1 year ago

ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025

ChromaDex to Present at the 37th Annual Roth Conference

Mar 11, 2025, 4:04 PM EDT - 1 year ago

ChromaDex to Present at the 37th Annual Roth Conference

wycliff
wycliff Jul. 14 at 8:48 PM
$NAGE https://clinicaltrials.gov/study/NCT07703137
1 · Reply
wycliff
wycliff Jul. 14 at 4:14 PM
$NAGE https://finance.yahoo.com/community/post/49689d6f-4de4-4010-87e3-f5d54a71e325
0 · Reply
wycliff
wycliff Jul. 14 at 4:02 PM
$NAGE https://www.linkedin.com/posts/receiving-rpd-designation-from-the-us-share-7482803623450742784-OTzE/?utm_source=share&utm_medium=member_ios&rcm=ACoAAAUGerIBOiyuZoO-6U9HRKRzZ48AD8YnjZA
0 · Reply
wycliff
wycliff Jul. 14 at 3:51 PM
$NAGE in response to impalas283 message maybe your answer is because they might be using NRH which is supposedly superior or an improvement over just using NR and they have the patents on it as well
1 · Reply
Impalas283
Impalas283 Jul. 14 at 12:56 PM
$NAGE The latest news does not make sense to me. The studies for these orphan diseases used Nicotine Riboside Chloride, (Tru Niagen) to obtain the results. Why wouldn't people with these diseases just use Tru Niagen Instead of an expensive prescription? Just another reason why people have lost faith in this company. Even long term holders are bailing out.
2 · Reply
wycliff
wycliff Jul. 14 at 12:20 AM
$NAGE https://finance.yahoo.com/community/post/1b995225-98af-4839-babe-44d28d74ff32
0 · Reply
MattManzanita
MattManzanita Jul. 13 at 11:56 PM
$NAGE Smart short sellers are getting out, but getting out too easily IMO: May be an image of text that says 'NAGE / Short Interest Niagen Bioscience, Inc. Common Stock (NAGE) Short Interest Settlement Short Interest 06/15/2026 4,394,606 Avg. Daily Share Volume 05/29/2026 4,498,798 789,556 05/15/2026- 4,715,950 652,114 04/30/2026 - 4,990,181 993 04/15/2026 - 5,401,652 126 03/31/2026- 5,453,364 5,453 03/13/2026- 5,496,661 598, 02/27/2026 -5,578,868 1,235, 02/13/2026 - 6,457,826 2,530, \ · Shorts have been steadily backing out since Valentines Day: They are squirming out of the net too easily.
0 · Reply
wycliff
wycliff Jul. 13 at 9:11 PM
$NAGE https://www.linkedin.com/posts/niagen-bioscience-announced-that-the-us-share-7482529797496209408-6IN3/?utm_source=share&utm_medium=member_ios&rcm=ACoAAAUGerIBOiyuZoO-6U9HRKRzZ48AD8YnjZA
0 · Reply
wycliff
wycliff Jul. 13 at 7:21 PM
$NAGE
0 · Reply
wycliff
wycliff Jul. 13 at 7:20 PM
$NAGE https://finance.yahoo.com/community/post/21f8de8b-4762-430e-ab69-7ad829a842b8
0 · Reply
wycliff
wycliff Jul. 13 at 7:16 PM
$NAGE https://www.linkedin.com/posts/niagenbioscience_join-dr-chris-d-m-nd-for-a-discussion-activity-7482503825258381312-eG7B?utm_source=share&utm_medium=member_ios&rcm=ACoAAAUGerIBOiyuZoO-6U9HRKRzZ48AD8YnjZA
0 · Reply
MattManzanita
MattManzanita Jul. 13 at 4:39 PM
$NAGE Regarding the new EU designation: "A company cannot easily command high pharmaceutical pricing or justify spending tens of millions on Phase 2/3 trials for a molecule that consumers can simultaneously buy over-the-counter for a fraction of the cost. Because **NB4168 possesses composition-of-matter patents**, it grants Niagen total exclusivity. No generic firm or competitor can copy the specific molecular structure, creating a highly defensible multi-billion-dollar market asset if approved."
0 · Reply
BarryMBarry
BarryMBarry Jul. 13 at 3:12 PM
$NAGE Seems like market doesn't care one bit about this news. We probably shouldn't either.
2 · Reply
tymtested
tymtested Jul. 13 at 2:34 PM
$NAGE appears the market views the news as positive foundational but not catalytic.
1 · Reply
wycliff
wycliff Jul. 13 at 1:42 PM
$NAGE https://finance.yahoo.com/healthcare/articles/niagen-bioscience-receives-exclusive-u-123200989.html
0 · Reply
GSP
GSP Jul. 13 at 1:14 PM
Final gapper watch list for Monday (con't): $LGPS $NAGE $VEEE .
0 · Reply
Bookshelf1974
Bookshelf1974 Jul. 13 at 12:55 PM
$NAGE NAD+, This is a peptide, improves health. Will be sold like other glps. No brainer here. $$$$$$
1 · Reply
GSP
GSP Jul. 13 at 12:39 PM
Updated gapper watch list (con't): $LGPS $NAGE .
0 · Reply
Volatility_Viking
Volatility_Viking Jul. 13 at 12:32 PM
$NAGE news
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 13 at 12:32 PM
$NAGE Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)
2 · Reply
wycliff
wycliff Jul. 12 at 11:57 PM
$NAGE https://share.gemini.google/1YVYS4ex8EhA
0 · Reply
wycliff
wycliff Jul. 12 at 11:40 PM
$NAGE https://share.gemini.google/FGBIvONVMSJA
0 · Reply